☆ 4.7 Article

Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Hematology

CD38 knocKout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide

Mark Gurney et al.

Summary: There is strong biological rationale for combining alloeneic natural killer (NK) cell therapies with a chimeric antigen receptor (CAR) to improve the targeting of acute myeloid leukemia (AML). However, CD38 expression on NK cells and its induction during ex vivo NK cell expansion pose challenges to the development of a CD38 CAR-NK cell therapy. This study successfully used gene editing technology to reduce CD38 expression in expanded NK cells, resulting in reduced fratricide and enhanced targeting of primary AML cells. Additionally, pretreatment of AML cells with all-trans retinoic acid further augmented the cytotoxic potential of CD38 CAR-NK cells. These findings support the investigation of CD38 knockdown - CD38 CAR-NK cells as a promising immunotherapeutic approach for AML treatment.

HAEMATOLOGICA (2022)

Add to Collection

Article Hematology

CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T cells

Marika Guercio et al.

Summary: A novel CAR.CD30 T cell therapy approach was designed and preclinically validated for chemotherapy-refractory or multiply relapsed CD30(+) NHL or HL. Through enhancing the co-stimulatory molecule CD28.OX40 in CAR.CD30 T cells, improved persistence and proliferation upon tumor encounter in vivo were achieved, leading to promising anti-tumor efficacy in HL and NHL xenograft mouse models.

HAEMATOLOGICA (2021)

Add to Collection

Review Oncology

Acute myeloid leukemia: current progress and future directions

Hagop Kantarjian et al.

Summary: Advancements in understanding and therapy of AML have been rapid, with targeted therapies such as venetoclax and FLT3 inhibitors being approved for various indications. Expertise is crucial in managing the complexity of AML treatment, tailored to the specific subentities for optimal outcomes.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Oncology

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells

Vincenzo Maria Perriello et al.

Summary: One-third of adult AML patients have NPM1 mutations, with high expression of CD123 identified as a potential target for therapy in NPM1-mutated leukemic cells, particularly in CD34(+)CD38(-) cells. Targeting CD123 may be effective for treating NPM1-mutated AML, especially in combination with FLT3 mutations.

CANCERS (2021)

Add to Collection

Review Oncology

CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success

Salvatore Fiorenza et al.

Summary: CAR-T cell therapy has shown promising potential for treating AML, but faces challenges such as antigenic heterogeneity and balancing therapy specificity and toxicity. Further research and clinical trials are essential for advancing AML CAR-T cell therapy.

BIODRUGS (2021)

Add to Collection

Review Immunology

Human NK cells, their receptors and function

Linda Quatrini et al.

Summary: NK cells, as part of innate lymphoid cells, play a crucial role in combating viral infections and controlling tumor growth. They are regulated by a variety of receptors to distinguish between healthy and altered cells, and have gained attention in tumor therapy research. Recent studies have focused on the origins, differentiation, and tissue distribution of NK cells.

EUROPEAN JOURNAL OF IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies

Marika Guercio et al.

Summary: This study investigates the inclusion of the inducible caspase 9 (iC9) suicide gene in CAR construct design as an effective safety switch to control malignant CAR+ B cells, potentially providing a safe CAR-T cell product even when starting from biological materials contaminated with leukemia blasts.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Oncology

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

Ying Gong et al.

Summary: NK cells, especially CAR-NK cells, play a crucial role in cancer treatment. Advances in CAR-NK technology show promising potential in efficiently targeting cancer cells with reduced side effects. These developments contribute to improving cancer treatment strategies.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Review Oncology

Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia

Noortje van Gils et al.

Summary: Standard induction chemotherapy is the first-line therapy for AML, but many patients face relapse or refractory disease. AML relapse is caused by therapy-resistant leukemia cells, with LSCs being considered the origin. The different states of treatment persisters and LSCs can be exploited to achieve optimal therapy response.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Hematology

Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy

Melissa R. Hines et al.

Summary: CAR T-cell therapy can lead to severe toxicity resembling carHLH, occurring in 14.8% of pediatric and young adult patients. Diagnosis and treatment of carHLH require suspicion and immunomodulation therapy, showing variable responses. Patients with carHLH have reduced response to therapy and overall survival compared to those without carHLH.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope

Alejandrina Hernandez-Lopez et al.

Summary: Cancer is a leading cause of death worldwide, and immunotherapy, particularly CAR-T cell therapy, has shown promise in treating patients who have not responded to traditional treatments. However, there are still challenges to overcome in making this technology a first-line clinical treatment.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Oncology

Strategy to prevent epitope masking in CAR.CD19+B-cell leukemia blasts

Concetta Quintarelli et al.

Summary: The presence of high percentage of leukemia blast contamination in patient-derived starting material did not affect the transduction level or expansion rate of CAR T-cell drug products. CAR design plays a crucial role in controlling CAR+ leukemia cells during manufacturing.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia

C. Quintarelli et al.

LEUKEMIA (2020)

Add to Collection

Article Medicine, General & Internal

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Enli Liu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Immunology

NK Cell-Based Immune Checkpoint Inhibition

Muhammad Khan et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Oncology

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo

Matteo Libero Baroni et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Oncology

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

Carlos A. Ramos et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Hematology

NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles

Simona Caruso et al.

SEMINARS IN HEMATOLOGY (2020)

Add to Collection

Article Oncology

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML

S. Haubner et al.

LEUKEMIA (2019)

Add to Collection

Article Oncology

A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia

Rosa Nguyen et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Editorial Material Hematology

Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?

Katherine D. Cummins et al.

HAEMATOLOGICA (2019)

Add to Collection

Article Biotechnology & Applied Microbiology

IFN-gamma and TNF-alpha aggravate endothelial damage caused by CD123-targeted CAR T cell

Yao Sun et al.

ONCOTARGETS AND THERAPY (2019)

Add to Collection

Review Medicine, General & Internal

NK Cell-Based Immunotherapy for Hematological Malignancies

Simona Sivori et al.

JOURNAL OF CLINICAL MEDICINE (2019)

Add to Collection

Article Hematology

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Daniel W. Lee et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Add to Collection

Article Medical Laboratory Technology

CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping

Anne E. Bras et al.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2019)

Add to Collection

Article Oncology

Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG plus AML

Sun Yao et al.

FRONTIERS IN ONCOLOGY (2019)

Add to Collection

Article Oncology

Preclinical Targeting of Human Acute Myeloid Leukemia Using CD4-specific Chimeric Antigen Receptor (CAR) T Cells and NK Cells

Huda Salman et al.

JOURNAL OF CANCER (2019)

Add to Collection

Review Oncology

PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?

Sylvain Simon et al.

ONCOIMMUNOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Jae H. Park et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article

Survival outcomes of CD34+CD38−LSCs and their expression of CD123 in adult AML patients

Asmaa M. Zahran et al.

Oncotarget (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia

Eduardo Laborda et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)

Add to Collection

Article Immunology

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity

Congcong Zhang et al.

FRONTIERS IN IMMUNOLOGY (2017)

Add to Collection

Article Multidisciplinary Sciences

Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15-transgenic NOG mouse

Ikumi Katano et al.

SCIENTIFIC REPORTS (2017)

Add to Collection

Article Hematology

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Rebecca A. Gardner et al.

BLOOD (2017)

Add to Collection

Article Cell & Tissue Engineering

No Identical Mesenchymal Stem Cells'' at Different Times and Sites: Human Committed Progenitors of Distinct Origin and Differentiation Potential Are Incorporated as Adventitial Cells in Microvessels

Benedetto Sacchetti et al.

STEM CELL REPORTS (2016)

Add to Collection

Review Hematology

T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia

Armen Mardiros et al.

CURRENT OPINION IN HEMATOLOGY (2015)

Add to Collection

Review Immunology

NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy

Wei Wang et al.

FRONTIERS IN IMMUNOLOGY (2015)

Add to Collection

Article Immunology

PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer

Fernando Concha-Benavente et al.

Journal for ImmunoTherapy of Cancer (2015)

Add to Collection

Article Hematology

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells

Saar Gill et al.

BLOOD (2014)

Add to Collection

Article Hematology

Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease

Clara Bueno et al.

HAEMATOLOGICA (2014)

Add to Collection

Article Hematology

Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor

Sarah Tettamanti et al.

BRITISH JOURNAL OF HAEMATOLOGY (2013)

Add to Collection

Article Hematology

Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum

Cristina Bergamaschi et al.

BLOOD (2012)

Add to Collection

Article Hematology

High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study

Francois Vergez et al.

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)

Add to Collection

Article Oncology

Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure

Michel Duval et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Immunology

Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene

Pablo Menendez et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2009)

Add to Collection

Article Cardiac & Cardiovascular Systems

Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells

Juan M. Melero-Martin et al.

CIRCULATION RESEARCH (2008)

Add to Collection

Review Immunology

Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias

Alessandro Moretta et al.

IMMUNOLOGICAL REVIEWS (2008)

Add to Collection

Article Biochemistry & Molecular Biology

Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment

Benedetto Sacchetti et al.

CELL (2007)

Add to Collection

Article Multidisciplinary Sciences

Natural killer cell signaling pathways

E Vivier et al.

SCIENCE (2004)

Add to Collection

Article Hematology

NOD/SCID/γcnull mouse:: an excellent recipient mouse model for engraftment of human cells

M Ito et al.

BLOOD (2002)

Add to Collection

Article Hematology

Elevated expression of IL-3Rα in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis

U Testa et al.

BLOOD (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.